Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease (Q38023517)

27 August 2017

Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

27 August 2017

1 reference

Dinesh Shrikrishna

1

1 reference

27 August 2017

Ronan Astin

series ordinal

2

1 reference

27 August 2017

Paul R Kemp

series ordinal

3

1 reference

27 August 2017

Nicholas S Hopkinson

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

123

1 reference

27 August 2017

8

1 reference

27 August 2017

487-498

1 reference

Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study

27 August 2017

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The global burden of disease, 1990–2020

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Systemic manifestations and comorbidities of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Corticospinal control of respiratory muscles in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Mortality in COPD: Role of comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin-converting enzyme and its clinical significance--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Skeletal muscle RAS and exercise performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

From viper's venom to drug design: treating hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Marked sympathetic activation in patients with chronic respiratory failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Neurohumoral activation as a link to systemic manifestations of chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

21 January 2018

Chymase: the other ACE?

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The pulmonary renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Reinventing the ACE inhibitors: some old and new implications of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II revisited: new roles in inflammation, immunology and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Oxidative stress and redox regulation of lung inflammation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Gene expression networks in COPD: microRNA and mRNA regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The pathogenesis of COPD and IPF: distinct horns of the same devil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Combined pulmonary fibrosis and emphysema syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II and the fibroproliferative response to acute lung injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin signalling in pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin-converting enzyme 2 in lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Pulmonary hypertension in advanced chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Categorization and impact of pulmonary hypertension in patients with advanced COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

ACE2, a promising therapeutic target for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Chronic obstructive pulmonary disease: consequences beyond the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The prevalence of quadriceps weakness in COPD and the relationship with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Gene expression in muscle in response to exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Mechanism of induction of muscle protein degradation by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

IKKbeta/NF-kappaB activation causes severe muscle wasting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin inhibition stimulates PPARgamma and the release of visfatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Physical exercise as an epigenetic modulator: Eustress, the "positive stress" as an effector of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Cellular markers of muscle atrophy in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Quadriceps myostatin expression in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Effects of estradiol, angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle in old female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Three-dimensional structure of the ion-coupled transport protein NhaA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Elite swimmers and the D allele of the ACE I/D polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

The angiotensin converting enzyme I/D polymorphism in Russian athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

ACE I/D and ACTN3 R/X polymorphisms and muscle function and muscularity of older Caucasian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Comorbidities in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Patterns of comorbidities in newly diagnosed COPD and asthma in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Sub-clinical left and right ventricular dysfunction in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Systemic manifestations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Controversies in treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Impact of statins and ACE inhibitors on mortality after COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Skeletal muscle dysfunction in COPD: clinical and laboratory observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120081

21 January 2018

Identifiers

DOI

10.1042/CS20120081

1 reference

27 August 2017

1 reference